These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26612407)

  • 1. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
    Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
    Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
    Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
    Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
    Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Uotani T; Furuta T
    Aliment Pharmacol Ther; 2015 Aug; 42(4):477-83. PubMed ID: 26075959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic resistance and
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    United European Gastroenterol J; 2017 Oct; 5(6):796-804. PubMed ID: 29026593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
    Matsuzaki J; Suzuki H; Nishizawa T; Hirata K; Tsugawa H; Saito Y; Okada S; Fukuhara S; Hibi T
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1643-5. PubMed ID: 22203601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
    Liou JM; Chen CC; Chen MJ; Chang CY; Fang YJ; Lee JY; Sheng WH; Wang HP; Wu MS; Lin JT
    J Antimicrob Chemother; 2011 Aug; 66(8):1847-52. PubMed ID: 21632579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
    Nishizawa T; Suzuki H; Nakagawa I; Iwasaki E; Masaoka T; Hibi T
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S167-70. PubMed ID: 19120892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea.
    Lee JW; Kim N; Nam RH; Park JH; Kim JM; Jung HC; Song IS
    Helicobacter; 2011 Aug; 16(4):301-10. PubMed ID: 21762270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
    Gu LY; Lin WW; Lu H; Chen XY; Ge ZZ; Li XB
    Helicobacter; 2011 Aug; 16(4):284-8. PubMed ID: 21762267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
    Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
    Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
    Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
    Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.